ATHENA-MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer

被引：0
|
作者：
Monk, Bradley J.
Parkinson, Christine
Lim, Myong Cheol
O'Malley, David M.
Oaknin, Ana
Wilson, Michelle K.
Coleman, Robert L.
Lorusso, Domenica
Oza, Amit M.
Ghamande, Sharad A.
Christopoulou, Athina
Prendergast, Emily
Demirkiran, Fuat
Littell, Ramey D.
Chudecka-Glaz, Anita M.
Morgan, Mark Aloysuis
Goble, Sandra M.
Hume, Stephanie
Fujiwara, Keiichi
Kristeleit, Rebecca
机构：
[1] Univ Arizona, Coll Med, Tucson, AZ 85721 USA
[2] Creighton Univ, Univ Sch Med, Phoenix, AZ USA
[3] Addenbrookes Hosp, Med Oncol, Cambridge, England
[4] Natl Canc Ctr Korea, Gynecol Oncol, Goyang Si, Gyeonggi Do, South Korea
[5] Ohio State Univ, Div Gynecol Oncol, James Canc Ctr, Columbus, OH 43210 USA
[6] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Gynaecol Canc Programme, Vail dHebron Barcelona Hosp Campus, Barcelona, Spain
[7] Auckland City Hosp, Dept Canc & Blood, Auckland, New Zealand
[8] US Oncol Res, The Woodlands, TX USA
[9] Fdn Univ Policlin A Gemelli IRCCS, MITO, Rome, Italy
[10] Fdn Univ Policlin A Gemelli IRCCS, Gynecol Oncol Unit, Rome, Italy
[11] Univ Cattolica Sacro Cuore, Rome, Italy
[12] Princess Margaret Hosp Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[13] Augusta Univ, Dept Obstet & Gynecol, Augusta, GA USA
[14] St Andrews Gen Hosp Patras, Med Oncol Unit, Patras, Greece
[15] Minnesota Oncol, Gynecol Oncol, Minneapolis, MN USA
[16] Istanbul Univ, Fac Med, Dept Gynecol Oncol, Istanbul, Turkey
[17] Kaiser Permanente Northern Calif, Gynecol Canc Program, San Francisco, CA USA
[18] Independent Publ Clin Hosp 2 PUM, Dept Surg Gynecol & Gynecol Oncol Adults & Girls, Szczecin, Poland
[19] Univ Penn Hlth Syst, Div Gynecol Oncol, Philadelphia, PA USA
[20] Clovis Oncol Inc, Biostat, Boulder, CO USA
[21] Clovis Oncol Inc, Clin Dev, Boulder, CO USA
[22] Saitama Med Univ, Int Med Ctr, Dept Gynecol Oncol, Hidaka, Saitama, Japan
[23] Guys & St Thomas NHS Fdn Trust, Dept Oncol, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA5500
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
    Monk, Bradley J.
    Coleman, Robert L.
    Fujiwara, Keiichi
    Wilson, Michelle K.
    Oza, Amit M.
    Oaknin, Ana
    O'Malley, David M.
    Lorusso, Domenica
    Westin, Shannon N.
    Safra, Tamar
    Herzog, Thomas J.
    Marme, Frederik
    Eskander, Ramez
    Lin, Kevin K.
    Shih, Danny
    Goble, Sandra
    Grechko, Nikolay
    Hume, Stephanie
    Maloney, Lara
    McNeish, Iain A.
    Kristeleit, Rebecca S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (12) : 1589 - 1594
  • [2] A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
    Monk, Bradley J.
    Parkinson, Christine
    Lim, Myong Cheol
    O'Malley, David M.
    Oaknin, Ana
    Wilson, Michelle K.
    Coleman, Robert L.
    Lorusso, Domenica
    Bessette, Paul
    Ghamande, Sharad
    Christopoulou, Athina
    Provencher, Diane
    Prendergast, Emily
    Demirkiran, Fuat
    Mikheeva, Olga
    Yeku, Oladapo
    Chudecka-Glaz, Anita
    Schenker, Michael
    Littell, Ramey D.
    Safra, Tamar
    Chou, Hung-Hsueh
    Morgan, Mark A.
    Drochytek, Vit
    Barlin, Joyce N.
    Van Gorp, Toon
    Ueland, Fred
    Lindahl, Gabriel
    Anderson, Charles
    Collins, Dearbhaile C.
    Moore, Kathleen
    Marme, Frederik
    Westin, Shannon N.
    McNeish, Iain A.
    Shih, Danny
    Lin, Kevin K.
    Goble, Sandra
    Hume, Stephanie
    Fujiwara, Keiichi
    Kristeleit, Rebecca S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (34) : 3952 - 3964
  • [3] Final safety results from ATHENA-MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer
    O'Malley, David M.
    Monk, Bradley J.
    Lim, Myong Cheol
    Pradera, Jose Fuentes
    Buscema, Joseph
    Wilson, Michelle K.
    De Vivo, Rocco
    Herzog, Thomas J.
    Zagouri, Flora
    Oza, Amit M.
    Mikheeva, Olga N.
    Diaz, John Paul
    Lisyanskaya, Alla Sergeevna
    Morris, Robert
    Bruchim, Ilan
    Craib, Marcia
    Connor, Christy
    Shih, Danny
    Fujiwara, Keiichi
    Kristeleit, Rebecca
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer
    Westin, Shannon N.
    Kristeleit, Rebecca S.
    Coleman, Robert L.
    Fujiwara, Keiichi
    Oza, Amit M.
    O'Malley, David M.
    Herzog, Thomas J.
    Marme, Frederik
    Oaknin, Ana
    Eskander, Ramez
    Lorusso, Domenica
    Safra, Tamar
    Korach, Jacob
    Lin, Kevin K.
    Shih, Danny
    Caunt, Lisa
    Goble, Sandra
    Hume, Stephanie
    Maloney, Lara
    McNeish, Iain
    Monk, Bradley J.
    CANCER RESEARCH, 2019, 79 (13)
  • [5] ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer
    Goh, Jeffrey C.
    Baron-Hay, Sally
    Bonaventura, Tony
    Buck, Martin
    Dean, Andrew
    Friedlander, Michael
    Gao, Bo
    Mileshkin, Linda
    Oehler, Martin K.
    Steer, Christopher
    Vi Nguyen
    Goble, Sandra
    Grechko, Nikolay
    Monk, Bradley J.
    Kristeleit, Rebecca S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 196 - 196
  • [6] ATHENA (GOG-3020/ENGOT-OV45): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF RUCAPARIB plus NIVOLUMAB FOLLOWING FRONT-LINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER
    Monk, B. J.
    Coleman, R. L.
    Fujiwara, K.
    Oza, A. M.
    Westin, S. N.
    O'Malley, D. M.
    Herzog, T. J.
    Marme, F.
    Oaknin, A.
    Eskander, R.
    Lorusso, D.
    Korach, J.
    Lin, K. K.
    Shih, D.
    Goble, S.
    Grechko, N.
    Hume, S.
    Maloney, L.
    McNeish, I.
    Kristeleit, R. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 1019 - 1020
  • [7] EFFICACY ANALYSIS BY DISEASE RISK SUBGROUP FOR THE PHASE 3 ATHENA-MONO STUDY (GOG3020/ENGOT-OV45) EVALUATING RUCAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED OVARIAN CANCER
    O'Malley, David
    Christopoulou, Athina
    Lim, Myong Cheol
    Diaz, John
    Demirkiran, Fuat
    Wilson, Michelle
    Jewell, Andrea
    Drochytek, Vit
    Bessette, Paul
    Morris, Robert
    Van Gorp, Toon
    Van Le, Linda
    Lindahl, Gabriel
    Eskander, Ramez
    Collins, Dearbhaile
    Goble, Sandra
    Hume, Stephanie
    Fujiwara, Keiichi
    Monk, Bradley
    Kristeleit, Rebecca
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A16 - A16
  • [8] ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib 1 the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
    Fujiwara, K.
    Chou, H-H.
    Kim, J-W.
    Tan, D. S.
    Tamura, K.
    Katsumata, N.
    Harano, K.
    Hasegawa, K.
    Hume, S.
    Jones, E.
    Goble, S.
    Sullivan, L.
    Shih, D.
    Coleman, R. L.
    McNeish, I.
    Monk, B.
    Kristeleit, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] ATHENA (GOG-3020/ENGOT-OV45; EUDRACT 2017-004557-17; NCT03522246): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB + THE PD-1 INHIBITOR NIVOLUMAB FOLLOWING FRONTLINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER (OC)
    Christopoulou, A.
    Marme, F.
    Oaknin, A.
    Lorusso, D.
    Safra, T.
    Lindahl, G.
    Chudecka-Glaz, A.
    Ciuleanu, T.
    Collins, D. C.
    Demirkiran, F.
    Lifrenko, I.
    Van Gorp, T.
    Coleman, R. L.
    Fujiwara, K.
    Oza, A. M.
    Westin, S. N.
    O'Malley, D. M.
    Herzog, T. J.
    Eskander, R.
    Wilson, M.
    Argire, S.
    Grechko, N.
    McNeish, I. A.
    Monk, B. J.
    Kristeleit, R. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A130 - A131
  • [10] ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC).
    Coleman, Robert L.
    Oza, Amit M.
    Lorusso, Domenica
    Aghajanian, Carol
    Oaknin, Ana
    Dean, Andrew
    Colombo, Nicoletta
    Weberpals, Johanne I.
    Clamp, Andrew
    Scambia, Giovanni
    Leary, Alexandra
    Holloway, Robert W.
    O'Malley, David M.
    Cameron, Terri
    Maloney, Lara
    Goble, Sandra
    Lin, Kevin
    Sun, James
    Giordano, Heidi
    Ledermann, Jonathan A.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 30 - +
12345